Sanofi-backed Expedition uses $115M series B to advance COPD drug on phase 2 journey

Posted inBiotechnology

Expedition Therapeutics has secured an oversubscribed $115 million series B financing from a line-up of big-name investors to propel its lead DPP1 inhibitor through phase 2.